Detail akcie Formycon online

Business Summary: Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Formycon AG revenues increased from EUR17.6M to EUR43.8M. Net income decreased 98% to EUR1.8M. Revenues reflect Switzerland (Country) segment increase from EUR5.5M to EUR29.6M, Germany (Country) segment increase of 17% to EUR14.2M. Net income was offset by Administrative Expenses increase of 20% to EUR5.5M (expense), Financial Expense - rest increase from EUR8K to EUR54K (expense).